Search 

Founded in 2001 and located in Zurich, Aravis is the first independent Swiss on-shore private equity house. With a track record of investment in the renewable energy and life science spaces, Aravis is currently managing more than a quarter of a billion Swiss francs.

With a long track record in life sciences and two life science investment funds (ARAVIS Biotech I and ARAVIS Biotech II), Aravis has held an early stage stake in some of the more eye-catching Swiss life science companies and has had over the years some notable exits through reverse takeover,  IPO or acquisition.

Aravis has a distinct and crafted approach to investment, taking a “hands on” approach that balances between finance, commercial assets and people. This approach transcends industry sector and with years of collected experience and expertise, Aravis has established a comprehensive investment platform that also incorporates accounting, regulatory and reporting expertise specific to Switzerland but also more widely. This means that Aravis is well placed to manage external funds for clients and institutions as well as putting together further internal funds focused on current and new industry sectors

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology.  The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies.  Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.

BerGenBio AS develops novel cancer therapeutics against highly invasive and drug resistant tumors; its R&D is directed towards targeting the tumor microenvironment, EMT and cancer stem cells. Our lead program BGB324 is a first in class Axl inhibitor will enter Ph1 in January 2013 and has shown preclinical activity in many cancers, including AML, NSCLC, breast, pancreatic and melanoma.

The company is built on proprietary state-of-the-art RNAi technology dedicated to identifying and validating novel cancer targets, other programs are in the drug discovery and lead optimization stages.

The company located in Bergen, Norway. It is funded by a syndicate of Norwegian investors and seeking qualified co-investors for a €12m series B at YE 2012.

BioCrea turns concepts into drug candidates. BioCrea is creating new drugs for the treatment of debilitating diseases of the central nervous system. With industry background and an international leadership team BioCrea provides new, first-in-class drug candidates for pharmaceutical companies.

BioCrea’s ability in inventing new treatments led to partnerships with Boehringer-Ingelheim, Pfizer, Wyeth and GlaxoSmithKline. They validate the company’s technology.

BioCrea is ideally positioned to provide new CNS drugs. Unique expertise and technology was integrated at BioCrea to generate new treatments. BioCrea’s patient-to-screen platform combines patient derived genetic information with the screening process and thus makes the outcome less dependent on biological hypothesis of CNS diseases.